Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitorXingyue He, Sai Murali Krishna Pulukuri, Jessica Riceberg et al.|Nature Chemical Biology|2017Cited by 228
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical modelsEric S. Lightcap, Dennis Huszar, Pengfei Yu et al.|Science Translational Medicine|2021Cited by 139
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase InhibitorsMichael E. Stokes, David Surguladze, Verónica Calvo et al.|Clinical Cancer Research|2023Cited by 27
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G. Thomson, Savithri Ramurthy, Baozhong Li et al.|Journal of Medicinal Chemistry|2024Cited by 16
A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.Arkadiusz Z. Dudek, J. L. Mesías Iglesias, Joyce O’Shaughnessy et al.|Journal of Clinical Oncology|2024Cited by 13